Description: At the conclusion of this session, attendees will be equipped to apply relative risk curves in their actuarial work, including the ability to examine dose-response relationships, apply population attributable fractions (PAFs), and develop customized risk models for cause-specific mortality and morbidity outcomes based on individual-level exposures to selected risk factors. These skills are becoming increasingly important as actuaries adopt novel applications of big data and dynamic health information to refine risk assessments and keep pace with global health trends.

Description: Both LDTI and IFRS 17 have introduced numerous new metrics with most companies having only crossed the finish line, just complying with what's needed for reporting due the complexity and large amounts of data required to simply comply. How do you leverage all the work you did to get proper business insights across the organization that tie back to these reporting metrics?

Description: Modern actuarial work, being quite data intensive, provides many opportunities for actuaries to use the statistical skills that are part of their basic training. Furthermore, modern computing allows us to analyze vast quantities of data intensively, and each package will provide statistical 'answers' to any questions the actuary might ask of it.

Description: Actuaries historically modeled new launches in pharmaceuticals by anticipating the expected change to the market basket. This became more complicated with the recent launches of gene and cell therapies as they address rare diseases. Rare conditions have low total member volume to study and some do not currently have a diagnosis code to identify them within claims data. Addressing this modeling challenge has been growing more important in the recent years with the number of therapies launching. What has the health care industry, and more specifically health care, done to enhance modeling and how should this be altered for the future? Additionally, historic modeling has sometimes incorporated a level of direct medical treatment cost offsets where studies have shown lower treatment costs are achievable. Can gene and cell financial modeling include cost offsets as well? And if so, what are suggested precautions or limitations to this effort?

Description: Enjoy an in-depth walkthrough of the facets of the lab testing world in this webcast. The agenda will include a discussion on genetic testing, which focuses on its general background, current trends and tests in the pipeline, as well as a focus on the approaches to achieve savings in lab testing. Finally, expect to check out sample actuarial analyses that will be used to identify areas of focus in lab management. Join us and take a deeper look into lab work in the actuarial health industry.

Description: Hear about some applications using quantile regression-derived individual and group claim distributions and how they may be used in various traditional health care modeling situations. The session will not focus on the technical use of quantile regression to obtain estimates of claim distributions, but more so is intended to focus on the uses of the distributions in actuarial modeling and the additive framework in assessing claims distributions. Presenters will show how actuaries can better assess risks by focusing on the individual- and group-specific claims distributions as opposed to traditional point-estimate-centric models.

Description: Pandemic modeling and its impact on the insurance and reinsurance business have been the subject of scrutiny during the COVID-19 pandemic. As the World Health Organization (WHO) has declared its end as a global health emergency, the focus of insurers and reinsurers turns to the possibility of future pandemics. Key to considering possible future pandemics is assessing what is needed to model pandemic risks. Our presentation will focus on providing you with the following: - The main principles around creating a well-established pandemic risk modeling framework, what they are and how you should build them into your model (As a reinsurer, this is core to our business, and we have unique global insights into performing it.) - A review of pandemic risk modeling strategies as well as an understanding of the inherent uncertainties of pandemic events - Lessons learned from COVID-19 and how we can apply them in assessing the possibility of future pandemics - An understanding of the link between future pandemic risk and the capital requirements

Description: Amid the growing adoption of AI/ML models for underwriting and pricing, Life and Annuity carriers are facing increasing regulation in North America on Model Risk Management (MRM) and the use of AI. Colorado has set a precedent in the US by requiring reporting in June 2024, with other states looking to follow suit. To ensure compliance, Chief Risk Officers and Heads of MRM, working with their business partners, will need to evolve their MRM and AI risk frameworks, enhance model validation capabilities, and strengthen governance. This session will present: - Key trends and challenges faced by carriers amid increasing model landscape complexity and regulatory expectations - Regulatory outlook and implications for carriers' MRM and AI risk programs - An approach to enhance MRM and AI risk frameworks, including specific model validation program updates to address the unique risks of AI/ML models - Opportunities to enhance both MRM validation effectiveness and efficiency through the adoption of more risk-based approaches, smart sourcing, and automation - Case studies of how leading carriers are evolving their MRM and AI risk programs Upon attending the session, the attendees will develop a good understanding of increasing regulatory expectations, the required MRM and AI risk framework enhancements, and approaches to design and execute an effective MRM validation program in a cost-efficient manner.

Description: Over the last 10 years, Artificial Intelligence (AI) healthcare foundation models have made tremendous strides when it comes to delivering highly accurate predictive results when compared to traditional models. This is especially true for models developed and trained on the ‘language’ of healthcare. When trained on healthcare data sequences (claims, EHR, CPT, ICD, pharmacy, lab, etc.), these models deliver far more accurate results as to WHAT beneficiary-level health events will occur and even WHEN they will occur.

Description: How do social determinants of health (SDOH) affect health outcomes in the United States, how might SDOH factors be incorporated into financing and risk adjustment of Medicaid, and what implications might this have for market participants?